Cedric Rossi

List of Publications by Year
in descending order

59 papers	2,063 citations	257450 24 h-index	254184 43 g-index
61 all docs	61 docs citations	61 times ranked	3372 citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 inhibitors in patients with Hodgkin lymphoma. European Journal of Cancer, 2022, 164, 114-116.	2.8	3
2	Baseline SUV<sub>max</sub> is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica, 2022, 107, 221-230.	3.5	17
3	Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study. Journal of Clinical Oncology, 2022, 40, 1091-1101.	1.6	11
4	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. Diagnostics, 2022, 12, 417.	2.6	9
5	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. Cancers, 2022, 14, 2532.	3.7	1
6	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood, 2021, 137, 877-887.	1.4	68
7	First–line treatment of double–hit and triple–hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. American Journal of Hematology, 2021, 96, 302-311.	4.1	32
8	Identification of novel, clonally stable, somatic mutations targeting transcription factors PAX5 and NKX2-3, the epigenetic regulator LRIF1, and BRAF in a case of atypical B-cell chronic lymphocytic leukemia harboring a t(14;18)(q32;q21). Journal of Physical Education and Sports Management, 2021, 7, a005934.	1.2	1
9	A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort. BMC Public Health, 2021, 21, 432.	2.9	9
10	3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma. Cancers, 2021, 13, 1490.	3.7	9
11	Prolonged in–hospital stay and higher mortality after Covid–19 among patients with <scp>non–Hodgkin</scp> lymphoma treated with B–cell depleting immunotherapy. American Journal of Hematology, 2021, 96, 934-944.	4.1	110
12	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. Blood, 2021, 137, 3495-3506.	1.4	22
13	Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Advances, 2021, 5, 3227-3239.	5.2	28
14	Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study. Blood Advances, 2021, 5, 3862-3872.	5.2	19
15	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
16	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, 2020, 105, 1032-1041.	3.5	29
17	CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies. Blood, 2020, 136, 2428-2436.	1.4	32
18	Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 2020, 4, 5607-5615.	5.2	222

#	Article	IF	Citations
19	Epidemiology, clinical picture and long–term outcomes of <i>FIP1L1–PDGFRA</i>–positive myeloid neoplasm with eosinophilia: Data from 151 patients. American Journal of Hematology, 2020, 95, 1314-1323.	4.1	37
20	Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. EClinicalMedicine, 2020, 27, 100549.	7.1	55
21	Accurate diagnosis of lymphoma on whole-slide histopathology images using deep learning. Npj Digital Medicine, 2020, 3, 63.	10.9	56
22	Monte Carlo dosimetry of a realistic multicellular model of follicular lymphoma in a context of radioimmunotherapy. Medical Physics, 2020, 47, 5222-5234.	3.0	5
23	Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department. Journal of Oncology Pharmacy Practice, 2020, 26, 1172-1179.	0.9	27
24	R-CHOP14 As a Standard of Care in Primary Mediastinal B Cell Lymphoma: A 10-YEARS Experience of Lysa Centers. Blood, 2020, 136, 20-21.	1.4	2
25	PVAG Regimen (Prednisone, Vinblastine, Doxorubicin, Gemcitabine) Used in Real-Life Setting in First Line Therapy for Elderly Classical Hodgkin Lymphoma Patients: A Retrospective Study of Lysa Centers. Blood, 2020, 136, 11-11.	1.4	1
26	A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma. Frontiers in Immunology, 2019, 10, 1943.	4.8	22
27	Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Reports, 2019, 26, 94-107.e7.	6.4	42
28	Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma. OncoImmunology, 2019, 8, 1554175.	4.6	53
29	Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients. Blood, 2019, 134, 1530-1530.	1.4	8
30	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. Blood, 2019, 134, 807-807.	1.4	2
31	A French Multicentric Prospective Cohort of 6000 Patients with Integrative Epidemiological, Clinical, Biological and Treatment Data to Improve Knowledge on Outcome of Lymphoma Patients: Pilot Phase Results of the Real World Data in Lymphoma and Survival in Adults (REALYSA) Study. Blood, 2019, 134, 4762-4762.	1.4	1
32	PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?. Oncotarget, 2019, 10, 4354-4355.	1.8	1
33	Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response. Blood, 2019, 134, 128-128.	1.4	0
34	Somatic Mutation Profile Analyzed By Next-Generation Sequencing in Relapsed/Refractory Follicular Lymphoma Treated with Idelalisib. Blood, 2019, 134, 1503-1503.	1.4	1
35	Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive Review. Targeted Oncology, 2018, 13, 287-308.	3.6	12
36	Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. Cancers, 2018, 10, 415.	3.7	19

#	Article	IF	Citations
37	[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers, 2018, 10, 145.	3.7	16
38	Efficacy of chemotherapy or chemo–anti–PD–1 combination after failed anti–PD–1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers. American Journal of Hematology, 2018, 93, 1042-1049.	4.1	87
39	A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers. Blood, 2018, 132, 1629-1629.	1.4	0
40	Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal Immunoglobulins. Frontiers in Immunology, 2017, 8, 1347.	4.8	33
41	Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget, 2017, 8, 44960-44975.	1.8	82
42	Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens. JCI Insight, 2017, 2, .	5.0	32
43	Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CT. Oncotarget, 2017, 8, 85110-85119.	1.8	2
44	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 2016, 7, 85573-85583.	1.8	13
45	Extreme hyperferritinemia in the setting of acute myeloid leukaemia: a case report of hemophagocytic lymphohistiocytosis. Biochemia Medica, 2016, 26, 255-259.	2.7	3
46	Outcomes of pregnancy in patients with congenital erythrocytosis. British Journal of Haematology, 2015, 170, 586-588.	2.5	3
47	Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma. PLoS ONE, 2015, 10, e0140830.	2.5	90
48	Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2015, 100, 472-478.	3.5	28
49	Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leukemia and Lymphoma, 2015, 56, 2876-2882.	1.3	13
50	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. Human Mutation, 2014, 35, 15-26.	2.5	101
51	Central nervous system involvement in chronic lymphocytic leukemia: uncommon manifestation with undefined therapeutic management. Leukemia and Lymphoma, 2014, 55, 1939-1941.	1.3	9
52	Interim ^{18}F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients. Journal of Nuclear Medicine, 2014, 55, 569-573.	5.0	76
53	Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1735-1743.	6.4	152
54	Autologous Stem Cell Transplantation: An Effective Salvage Therapy in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2013, 19, 445-449.	2.0	62

#	Article	IF	Citations
55	Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population€based study of 327 patients. British Journal of Haematology, 2013, 160, 251-254.	2.5	63
56	Perirenal fibrosis: make your diagnosis. CKJ: Clinical Kidney Journal, 2013, 6, 543-544.	2.9	1
57	Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene(s)?). European Journal of Haematology, 2013, 91, 361-368.	2.2	38
58	Comparison Of Hevylite„¢ Assay and Plasma Cell Immunophenotyping For Response Evaluation and Residual Disease Characterisation In IgA Myeloma. Blood, 2013, 122, 5319-5319.	1.4	0
59	Extranodal classical Hodgkin lymphoma involving the spinal cord: case report and review of the literature. CNS Oncology, 0, , .	3.0	0